NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
November 05 2018 - 11:23PM
Business Wire
Update on Off-The-Shelf CD16 Targeted NK
Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data
Analysis for Pancreatic Cancer, Triple Negative Breast Cancer &
Head and Neck Cancer Trials
NantKwest (NASDAQ: NK), a leading, clinical-stage natural killer
cell-based therapeutics company, today announced that the company
will be making multiple presentations associated with the company’s
off-the-shelf CD16 targeted NK cell (hanK) and NANT Cancer Vaccine
platform at the upcoming Society for Immunotherapy of Cancer (SITC)
Conference which runs from November 7 – 11 in Washington D.C.
SITC Conference Details:
Title:
First in human data in advanced solid
tumors of NANT Cancer Vaccine: A novel temporospatial orchestration
of the innate (NK) & adaptive immune system to induce antigen
cascade & immunogenic cell death
Session: Immune Escape: Currently Understanding of
Mechanisms and Advances in Therapeutics Approaches
Date/Time: Wednesday, November 7, 2018, 5:45pm EST Type:
Oral Presentation Title:
NANT Cancer Vaccine an orchestration of
immunogenic cell death by overcoming immune suppression and
activate NK and T cell therapy in patients with third-line or
greater metastatic pancreatic cancer
Date: Friday, November 9, 2018 Type: Poster
Presentation/Abstract #P713 Location: Hall E
Title:
NANT Cancer Vaccine an orchestration of
immunogenic cell death by overcoming immune suppression and
activate NK and T cell therapy in patients with third-line or
greater TNBC and head & neck cancer
Date: Saturday, November 10, 2018 Type: Poster
Presentation/Abstract #P310 Location: Hall E
About NantKwest Inc.
NantKwest is an innovative clinical-stage immunotherapy company
focused on harnessing the power of the innate immune system by
using the natural killer cell to treat cancer, infectious diseases
and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer cells are ancient cells in the human
body designed to recognize and detect cells under stress or
infected. The NantKwest “off-the-shelf” activated Natural Killer
(NK) platform has the capacity to destroy cancer and virally
infected cells from the body. The safety of our NK cells as well as
their activity against a broad range of cancers have been tested in
multiple phase 1 clinical trials in the United States, Canada and
Europe. In addition to our NK cells capability to be administered
in the outpatient setting as an “off-the-shelf” living drug, it
serves as a universal cell-based therapy without need for
individualized patient matching. Moreover, our NK cell-based
platform has been bioengineered to incorporate chimeric antigen
receptors (CARs) and antibody receptors to further optimize
targeting and potency in the therapeutic disease.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying the Company will be successful in improving the treatment
of cancer. Risks and uncertainties related to this endeavor
include, but are not limited to, obtaining FDA approval of our NK
cells as well as other therapeutics as part of the NANT Cancer
Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Quarterly Report on Form 10-Q for the quarter ended June 30,
2018. These forward-looking statements speak only as of the date
hereof, and we disclaim any obligation to update these statements
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181105006066/en/
NantKwest Inc.Media Contact:Jen Hodson,
562-397-3639jhodson@nantworks.comorInvestor Contact:David Pyrce,
951-551-0949david.pyrce@nantkwest.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Sep 2023 to Sep 2024